BIO Stock Overview
Biotest Aktiengesellschaft desarrolla, fabrica y vende productos farmacéuticos biológicos y biotecnológicos en Alemania y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €41.80 |
| 52 Week High | €44.00 |
| 52 Week Low | €39.60 |
| Beta | 0.26 |
| 1 Month Change | -0.48% |
| 3 Month Change | 0.48% |
| 1 Year Change | -1.42% |
| 3 Year Change | 40.74% |
| 5 Year Change | 69.92% |
| Change since IPO | 842.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.4% | 4.5% | -1.3% |
| 1Y | -1.4% | -13.9% | 4.1% |
Rentabilidad frente al sector: BIO superó al sector German Biotechs , que obtuvo un rendimiento del -13.9% el año pasado.
Rentabilidad vs. Mercado: BIO obtuvo unos resultados inferiores a los del mercado German, que fue del 0.1% el año pasado.
Price Volatility
| BIO volatility | |
|---|---|
| BIO Average Weekly Movement | 1.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: BIO no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BIO (1%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,426 | Peter Janssen | https://www.biotest.com |
Biotest Aktiengesellschaft desarrolla, fabrica y vende productos farmacéuticos biológicos y biotecnológicos en Alemania y a escala internacional. Opera a través de tres segmentos: Unión Europea, Resto del Mundo y Apátridas. La empresa se especializa principalmente en las áreas terapéuticas de inmunología clínica, hematología y medicina intensiva.
Biotest Aktiengesellschaft Fundamentals Summary
| BIO fundamental statistics | |
|---|---|
| Market cap | €1.41b |
| Earnings (TTM) | €127.00m |
| Revenue (TTM) | €684.60m |
9.1x
P/E Ratio1.7x
P/S RatioIs BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO income statement (TTM) | |
|---|---|
| Revenue | €684.60m |
| Cost of Revenue | €404.30m |
| Gross Profit | €280.30m |
| Other Expenses | €153.30m |
| Earnings | €127.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 3.21 |
| Gross Margin | 40.94% |
| Net Profit Margin | 18.55% |
| Debt/Equity Ratio | 126.7% |
How did BIO perform over the long term?
See historical performance and comparison